Vericel

VCEL US Health Care Biotechnology
S&P 600
$38.34
+1.24%
Delayed · cached 15 min

Fair value analysis

VCEL
Vericel
Health CareBiotechnology
$38.34
Close used for this calculation
$8.98Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
40/100
Profitability19/25
Returns0/25
Balance Sheet15/25
Efficiency6/25
Growth12/25
Average
Quality radar
40Prof.19/25Ret.0/25Eff.6/25B.Sht15/25Growth12/25

Consensus fair value

$8.98
Above FV
▼ -76.6% against the close used
Model range $3.15 – $9.60
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$3.15Fair value$8.98Bull$9.60
FairClose
52-week traded range
52W low $29.3452W high $48.31

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Vericel closed at $38.34, 326.9% above the consensus fair value of $8.98 drawn from 7 valuation models.

Financial DNA score 40/100 — Average. P/E of 119.8x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
$9.52
-75.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
P/E Fair Value
$6.40
-83.3%
EPS × 20x (sector P/E)
EPS=0.32, Sector P/E=20x
Peter Lynch (PEG)
$9.60
-75.0%
EPS × Growth% (PEG = 1 is fair)
EPS=0.32, g=30%
EV/EBITDA
$7.88
-79.5%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=22.59M
Book Value (P/B)
$3.15
-91.8%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=7.07, ROE=4.5%, g=6%, r=10%
Reverse DCF
$38.34
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 31.7% | Historical: 40%
Margin of Safety
$5.97
-84.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=7.96, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.